Increased fracture callus mineralization and strength in cathepsin K knockout mice

Bone

Volumn 66, Issue , 2014, Pages 72-81

  Gentile, Michael A ^a   Soung, Do Y ^b   Horrell, Carlyle ^a   Samadfam, Rana ^c   Drissi, Hicham ^b   Duong, Le T ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^c CHARLES RIVER LABORATORIES   (United States)

Author keywords

Cathepsin K; Closed stabilized fracture model; Fracture healing; Osteoblast; Osteoclast

Indexed keywords

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOMECHANICS; BONE DENSITY; BONE MASS; BONE MINERALIZATION; BONE REMODELING; BONE STRENGTH; CALLUS; CELL COUNT; CELL SURFACE; CONTROLLED STUDY; CORTICAL BONE; ENZYME INHIBITION; ENZYME MECHANISM; EX VIVO STUDY; FEMALE; FEMUR FRACTURE; GENE DELETION; IN VIVO STUDY; KNOCKOUT MOUSE; MICRO-COMPUTED TOMOGRAPHY; MORPHOMETRICS; MOUSE; NONHUMAN; OSSIFICATION; OSTEOCLAST; OSTEOID; RADIOGRAPHY; TRABECULAR BONE; WILD TYPE; ANIMAL; C57BL MOUSE; DEFICIENCY; FRACTURE HEALING; METABOLISM; ORGAN SIZE; OSTEOBLAST; PATHOLOGY; PATHOPHYSIOLOGY;

CATHEPSIN K;

ANIMALS; BIOMECHANICAL PHENOMENA; BONE REMODELING; BONY CALLUS; CALCIFICATION, PHYSIOLOGIC; CATHEPSIN K; CELL COUNT; FEMALE; FEMORAL FRACTURES; FRACTURE HEALING; GENE DELETION; MICE, INBRED C57BL; MICE, KNOCKOUT; ORGAN SIZE; OSTEOBLASTS; OSTEOCLASTS;

EID: 84902684559     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2014.04.032     Document Type: Article

References (50)

1. Kanis J.A. WHO Technical Report 2007, vol. 66. University of Sheffield, UK.
2. Cummings S.R., Melton L.J. Epidemiology and outcomes of osteoporotic fractures. Lancet 2002, 359:1761-1767.
3. Dempster DW, Lambing CL, Kostenuik PJ, Grauer A. Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data. Clin Ther 2012, 34:521-536.
4. Rodan G.A., Balena R. Bisphosphonates in the treatment of metabolic bone diseases. Ann Med 1993, 25:521-536.
5. Baron R., Ferrari S., Russell R.G. Denosumab and bisphosphonates: different mechanisms of action and effects. Bone 2011, 48:677-692.
6. Gerstenfeld L.C., Cullinane D.M., Barnes G.L., Graves D.T., Einhorn T.A. Fracture healing as a post-natal developmental process: molecular, spatial, and temporal aspects of its regulation. J Cell Biochem 2003, 88:873-884.
7. Peter C.P., Cook W.O., Nunamaker D.M., Provost M.T., Seedor J.G., Rodan G.A. Effect of alendronate on fracture healing and bone remodeling in dogs. J Orthop Res 1996, 14:74-79.
8. Gerstenfeld L.C., Sacks D.J., Pelis M., Mason Z.D., Graves D.T., Barrero M., et al. Comparison of effects of the bisphosphonate alendronate versus the RANKL inhibitor denosumab on murine fracture healing. J Bone Miner Res 2009, 24:196-208.
9. Masarachia P.J., Pennypacker B.L., Pickarski M., Scott K.R., Wesolowski G.A., Smith S.Y., et al. Odanacatib reduces bone turnover and increases bone mass in the lumbar spine of skeletally mature ovariectomized rhesus monkeys. J Bone Miner Res 2012, 27:509-523.
10. Pennypacker B.L., Duong L.T., Cusick T.E., Masarachia P.J., Gentile M.A., Gauthier J.Y., et al. Cathepsin K inhibitors prevent bone loss in estrogen-deficient rabbits. J Bone Miner Res 2010, 26:252-262.
11. Williams D.S., McCracken P.J., Purcell M., Pickarski M., Mathers P.D., Savitz A.T., et al. Effect of odanacatib on bone turnover markers, bone density and geometry of the spine and hip of ovariectomized monkeys: a head-to-head comparison with alendronate. Bone 2013, 56(2):489-496.
12. Jerome C., Missbach M., Gamse R. Balicatib, a cathepsin K inhibitor, stimulates periosteal bone formation in monkeys. Osteoporos Int 2013, 23:339-349.
13. Cusick T., Chen C.M., Pennypacker B.L., Pickarski M., Kimmel D.B., Scott B.B., et al. Odanacatib treatment increases hip bone mass and cortical thickness by preserving endocortical bone formation and stimulating periosteal bone formation in the ovariectomized adult rhesus monkey. J Bone Miner Res 2012, 27:524-537.
14. Stroup G.B., Lark M.W., Veber D.F., Bhattacharyya A., Blake S., Dare L.C., et al. Potent and selective inhibition of human cathepsin K leads to inhibition of bone resorption in vivo in a nonhuman primate. J Bone Miner Res 2001, 16:1739-1746.
15. Robichaud J., Bayly C., Oballa R., Prasit P., Mellon C., Falgueyret J.P., et al. Rational design of potent and selective NH-linked aryl/heteroaryl cathepsin K inhibitors. Bioorg Med Chem Lett 2004, 14:4291-4295.
16. Gauthier J.Y., Chauret N., Cromlish W., Desmarais S., Duong L.T., Falgueyret J.P., et al. The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K. Bioorg Med Chem Lett 2008, 18:923-928.
17. Langdahl B., Binkley N., Bone H., Gilchrist N., Resch H., Portales J.R., et al. Odanacatib in the treatment of postmenopausal women with low bone mineral density: 5years of continued therapy in a phase 2 study. J Bone Miner Res 2012, 27(11):2251-2258.
18. Pennypacker B., Shea M., Liu Q., Masarachia P., Saftig P., Rodan S., et al. Bone density, strength, and formation in adult cathepsin K (-/-) mice. Bone 2009, 44:199-207.
19. Saftig P., Hunziker E., Everts V., Jones S., Boyde A., Wehmeyer O., et al. Functions of cathepsin K in bone resorption. Lessons from cathepsin K deficient mice. Adv Exp Med Biol 2000, 477:293-303.
20. Saftig P., Hunziker E., Wehmeyer O., Jones S., Boyde A., Rommerskirch W., et al. Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc Natl Acad Sci U S A 1998, 95:13453-13458.
21. Lotinun S., Kiviranta R., Matsubara T., Alzate J.A., Neff L., Luth A., et al. Osteoclast-specific cathepsin K deletion stimulates S1P-dependent bone formation. J Clin Invest 2013, 123:666-681.
22. Kakar S., Einhorn T.A., Vora S., Miara L.J., Hon G., Wigner N.A., et al. Enhanced chondrogenesis and Wnt signaling in PTH-treated fractures. J Bone Miner Res 2007, 22:1903-1912.
23. Toben D., Schroeder I., El Khassawna T., Mehta M., Hoffmann J.E., Frisch J.T., et al. Fracture healing is accelerated in the absence of the adaptive immune system. J Bone Miner Res 2011, 26:113-124.
24. Bonnarens F., Einhorn T.A. Production of a standard closed fracture in laboratory animal bone. J Orthop Res 1984, 2:97-101.
25. Soung Do Y., Talebian L., Matheny C.J., Guzzo R., Speck M.E., Lieberman J.R., et al. Runx1 dose-dependently regulates endochondral ossification during skeletal development and fracture healing. J Bone Miner Res 2012, 27:1585-1597.
26. Soung Do Y., Gentile M.A., Duong L.T., Drissi H. Effects of pharmacological inhibition of cathepsin K on fracture repair in mice. Bone 2013, 55:248-255.
27. Bouxsein M.L., Boyd S.K., Christiansen B.A., Guldberg R.E., Jepsen K.J., Muller R. Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J Bone Miner Res 2010, 25:1468-1486.
28. Yamamoto M., Fisher J.E., Gentile M., Seedor J.G., Leu C.T., Rodan S.B., et al. The integrin ligand echistatin prevents bone loss in ovariectomized mice and rats. Endocrinology 1998, 139:1411-1419.
29. Safadi F.F., Thornton P., Magiera H., Hollis B.W., Gentile M., Haddad J.G., et al. Osteopathy and resistance to vitamin D toxicity in mice null for vitamin D binding protein. J Clin Invest 1999, 103:239-251.
30. Parfitt A.M., Drezner M.K., Glorieux F.H., Kanis J.A., Malluche H., Meunier P.J., et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 1987, 2:595-610.
31. Gerstenfeld L.C., Wronski T.J., Hollinger J.O., Einhorn T.A. Application of histomorphometric methods to the study of bone repair. J Bone Miner Res 2005, 20:1715-1722.
32. An Y.H., Friedman R.J., Draughn R.A. Animal models of bone fracture or osteotomy. Animal Models in Orthopaedic Research 1999, 197-217. CRC Press, Boca Raton.
33. Endo K., Sairyo K., Komatsubara S., Sasa T., Egawa H., Ogawa T., et al. Cyclooxygenase-2 inhibitor delays fracture healing in rats. Acta Orthop 2005, 76:470-474.
34. Yamane H., Sakai A., Mori T., Tanaka S., Moridera K., Nakamura T. The anabolic action of intermittent PTH in combination with cathepsin K inhibitor or alendronate differs depending on the remodeling status in bone in ovariectomized mice. Bone 2009, 44:1055-1062.
35. Eisman J.A., Bone H.G., Hosking D.J., McClung M.R., Reid I.R., Rizzoli R., et al. Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect. J Bone Miner Res 2011, 26:242-251.
36. Soung D.Y., Gentile M.A., Duong L.T., Drissi H. Effects of pharmacological inhibition of cathepsin K on fracture repair in mice. Bone 2013, 55(1):248-255.
37. Falgueyret J.P., Desmarais S., Oballa R., Black W.C., Cromlish W., Khougaz K., et al. Lysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off-target cathepsins and reduced functional selectivity. J Med Chem 2005, 48:7535-7543.
38. Dejica V.M., Mort J.S., Laverty S., Antoniou J., Zukor D.J., Tanzer M., et al. Increased type II collagen cleavage by cathepsin K and collagenase activities with aging and osteoarthritis in human articular cartilage. Arthritis Res Ther 2012, 14:R113.
39. Dejica V.M., Mort J.S., Laverty S., Percival M.D., Antoniou J., Zukor D.J., et al. Cleavage of type II collagen by cathepsin K in human osteoarthritic cartilage. Am J Pathol 2008, 173:161-169.
40. Uusitalo H., Hiltunen A., Soderstrom M., Aro H.T., Vuorio E. Expression of cathepsins B, H, K, L, and S and matrix metalloproteinases 9 and 13 during chondrocyte hypertrophy and endochondral ossification in mouse fracture callus. Calcif Tissue Int 2000, 67:382-390.
41. Kumar S., Dare L., Vasko-Moser J.A., James I.E., Blake S.M., Rickard D.J., et al. A highly potent inhibitor of cathepsin K (relacatib) reduces biomarkers of bone resorption both in vitro and in an acute model of elevated bone turnover in vivo in monkeys. Bone 2007, 40:122-131.
42. Stoch S.A., Zajic S., Stone J., Miller D.L., Van Dyck K., Gutierrez M.J., et al. Effect of the cathepsin K inhibitor odanacatib on bone resorption biomarkers in healthy postmenopausal women: two double-blind, randomized, placebo-controlled phase I studies. Clin Pharmacol Ther 2009, 86:175-182.
43. Kiviranta R., Morko J., Alatalo S.L., NicAmhlaoibh R., Risteli J., Laitala-Leinonen T., et al. Impaired bone resorption in cathepsin K-deficient mice is partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL/OPG ratio. Bone 2005, 36:159-172.
44. Leung P., Pickarski M., Zhuo Y., Masarachia P.J., Duong L.T. The effects of the cathepsin K inhibitor odanacatib on osteoclastic bone resorption and vesicular trafficking. Bone 2011, 49:623-635.
45. Li C.Y., Jepsen K.J., Majeska R.J., Zhang J., Ni R., Gelb B.D., et al. Mice lacking cathepsin K maintain bone remodeling but develop bone fragility despite high bone mass. J Bone Miner Res 2006, 21:865-875.
46. Kim M.K., Kim H.D., Park J.H., Lim J.I., Yang J.S., Kwak W.Y., et al. An orally active cathepsin K inhibitor, furan-2-carboxylic acid, 1-{1-[4-fluoro-2-(2-oxo-pyrrolidin-1-yl)-phenyl]-3-oxo-piperidin-4-ylcarbamoyl}-cyclohexyl)-amide (OST-4077), inhibits osteoclast activity in vitro and bone loss in ovariectomized rats. J Pharmacol Exp Ther 2006, 318:555-562.
47. Lau K.H., Kothari V., Das A., Zhang X.B., Baylink D.J. Cellular and molecular mechanisms of accelerated fracture healing by COX2 gene therapy: studies in a mouse model of multiple fractures. Bone 2013, 53:369-381.
48. Murata K., Ito H., Yoshitomi H., Yamamoto K., Fukuda A., Yoshikawa J., et al. Inhibition of miR-92a enhances fracture healing via promoting angiogenesis in a model of stabilized fracture in young mice. J Bone Miner Res 2014, 29:316-326.
49. Naik A.A., Xie C., Zuscik M.J., Kingsley P., Schwarz E.M., Awad H., et al. Reduced COX-2 expression in aged mice is associated with impaired fracture healing. J Bone Miner Res 2009, 24:251-264.
50. Everts V., Hou W.S., Rialland X., Tigchelaar W., Saftig P., Bromme D., et al. Cathepsin K deficiency in pycnodysostosis results in accumulation of non-digested phagocytosed collagen in fibroblasts. Calcif Tissue Int 2003, 73:380-386.